日大医学雑誌
Online ISSN : 1884-0779
Print ISSN : 0029-0424
総説
前立腺癌の化学予防
山口 健哉
著者情報
キーワード: 前立腺癌, 化学予防
ジャーナル フリー

69 巻 (2010) 2 号 p. 75-81

詳細
PDFをダウンロード (121K) 発行機関連絡先
抄録

Facing an increasingly aged society, prostate cancer screening, mainly by prostate-specific antigen (PSA), is increasing all over the world, even in Japan. Newly diagnosed prostate cancer has been dramatically increasing and the number of affected patients is estimated to be 78000 in 2020 in Japan. Three-quarters of patients with prostate cancer are older than 65 years old, which makes the cancer suitable for chemoprevention. Herein, we introduce a typical clinical procedure in the diagnosis and treatment of this disease, and report the basic, clinical aspects and prospects of chemoprevention. Within the report, the results in four of phase 3 trials, including the Physicians Health Study II (PHS II), Selenium and Vitamin E Chemoprevention Trial (SELECT), Prostate Cancer Prevention Trial (PCPT) and Reduction by Dutasteride of Prostate Cancer Events Trial (REDUCE) are presented and discussed.

著者関連情報
© 2010 日本大学医学会
前の記事 次の記事

閲覧履歴
feedback
Top